Literature DB >> 9678685

Antibody to hepatitis B e positive hepatitis induced by withdrawal of steroid therapy for polymyositis: response to interferon-alpha and cyclosporin A.

K Nakanishi1, M Ishikawa, M Nakauchi, A Sakurai, K Doi, Y Taniguchi.   

Abstract

A 57-year-old woman was admitted with symmetrical proximal muscle weakness, liver dysfunction, abnormal muscle enzymes, and she was an antibody to hepatitis B e (anti-HBe) positive hepatitis B virus (HBV) carrier. Biopsy of her left quadriceps femoris showed myositis, so prednisolone was started at 40 mg/day. However, her hepatic function deteriorated and liver biopsy after 4 months showed acute hepatitis with partial submassive necrosis. Treatment with interferon-alpha and cyclosporin A progressively reduced the transaminase and HBV-DNA levels. Early treatment with interferon-alpha plus cyclosporin A can control exacerbation of hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9678685     DOI: 10.2169/internalmedicine.37.519

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 2.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

Review 3.  Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

Authors:  Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 5.  Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.

Authors:  Dandan Xuan; Yiqi Yu; Linyun Shao; Jiali Wang; Wenhong Zhang; Hejian Zou
Journal:  Clin Rheumatol       Date:  2013-12-11       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.